Journal of the American Medical Association, Original Investigation article
JAMA, October 24/31, 2023
A randomized, double-blind, placebo controlled clinical trial of 3797 patients from 124 hospitals in China within 24 hours of onset of ST-segment elevation myocardial infarction (STEMI)
What’s Interesting about this article?
- Traditional Chinese medicines are the most commonly prescribed therapeutic agents worldwide.
- There are around 12,800 traditional Chinese medicines. Most are derived from plants or from mixtures of animal and mineral components. Tongxinluo is a traditional Chinese medicine derived from a mixture of plants and animal products.
- This study found significant clinical improvement with Tongxinluo at 30 days and 1-year.
- Very few Chinese medicines have been studied using Western world randomized controlled studies. This was a rigorous study by Chinese investigators that meets the standards of Evidence-based Medicine.
- An accompanying editorial by Richard Bach, MD points out that ingredients in Tongxinluo include “the dried bodies of cockroaches, centipedes, leeches, cicadas and scorpions”.
- It is not surprising that the major adverse drug reactions reported with Tongxinluo were stomach discomfort and nausea. However, the relative risk reduction of 37% for adverse outcomes is very impressive and warrants further RCTs.
Disclaimer: Article of the Week selections by JournalDoc physicians are independent, unbiased and have no commercial conflict of interest. JournalDoc does not support or endorse the findings or opinions expressed in the article. Findings in the article may need to be supported by further research and/or the consensus of experts.